New Clinical Trial for patients with Advanced Medullary Thyroid Cancer

April 9th, 2012

An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease


10 countries, 34 sites plus seven back-up sites

Hopefully five UK centres – Cardiff, Christie, Royal Marsden, Barts and Newcastle – will be taking part
80 patients required, 14 months recruitment period expected

Inclusion Criteria of Interest:

  • Confirmed histological diagnosis of MTC
  • Unresectable locally advanced and/or metastatic
  • Hereditary or sporadic
  • Objective disease progression within the previous 14 months and/or Symptomatic

Currently awaiting MREC and MHRA approval in the UK so recruitment may be able to commence in June/July 2012

[April 2012]

 

Leave a Reply

Your email address will not be published. Required fields are marked *

We are available on this number on Tuesdays and Fridays from 10 am to 4 pm. Outside these times, please leave a message on our answer phone and we will get back to you as soon as we can.